Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.65 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.65 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.65 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.65 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.65 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906669 | 1.00 | CYP2C9 (0.65) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7906676 | 1.00 | CYP2C9 (0.65) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7913011 | 0.89 | PSEN1 (0.52) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7905581 | 0.89 | PSEN1 (0.52) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24913593 | 0.89 | PSEN1 (0.52) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL956513 | 0.84 | PSEN1 (0.75) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL956227 | 0.84 | PSEN1 (0.75) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL956350 | 0.84 | PSEN1 (0.75) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL717975 | 0.82 | CYP2C9 (0.68) | CYP2C9PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL954828 | 0.82 | CYP2C9 (0.75) | CYP2C9PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029372-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-01-26 | — | — | US | disclosed |
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| EP-2615090-A1 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2401276-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029372-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | TNNI3, TNNT2, TNNC1 | CYP2C9 4783/4885PSEN1 15/4885PSEN2 26/4885 |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | BACE1, APP, PSEN1 | CYP2C9 2129/4885PSEN1 3/4885PSEN2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.